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Intensity-modulated  
radiotherapy in head and 
neck cancer: How safe is 
safe?
To the Editor: Intensity-
modulated radiotherapy (IMRT) 
has largely replaced conventional ir-
radiation for the treatment of head 
and neck cancer in the majority of 
radiation oncology clinics. This rap-
id implementation came amidst a 
stunning lack of level I evidence as-
sessing the efficacy, and more impor-
tantly, the safety of IMRT in head 
and neck cancer. Recently, Nutting 
and collegues1 reported the third 
randomized controlled trial assess-
ing the efficacy of parotid-sparing 
IMRT for head and neck squamous 
cell carcinoma. Like the results of 
previously published trials,2,3 this 
large multicenter study lays a rigid 
framework supporting the use of 
IMRT for parotid gland sparing 
in head and neck cancer.  However, 
this report raises several subtle 
IMRT-related safety concerns. The 
authors state that 7 locoregional 
recurrences were detected in the 
conventional radiotherapy group as 
opposed to 12 in the IMRT group. 
The spatial distribution of locore-
gional recurrence was related to the 
“high-dose volume” or the “electively 
irradiated neck”. Although locore-
gional progression-free survival is 
not a primary assessable endpoint, 
this study demonstrated a trend 
towards worsened locoregional 
control in the IMRT group. IMRT 
plans are generally characterized by 
dramatic dose gradients and as such, 
the deleterious effects of steep dose 
fall-offs on locoregional disease 
control cannot be dismissed. The 
spatial distribution of locoregional 
recurrence is imperative in address-
ing the safety of IMRT in head and 
neck cancer. The authors state that 
the majority of locoregional failures 
were located in the “high-dose vol-
ume” and none in the spared parotid 
tissue. However, they did not report 
the geographical distribution of re-
currence to the 95% isodose as been 
previously reported by Eisbruch et 
al.4 Co-registration of the computed 
tomography (CT) image harboring 
local failure with the corresponding 
planning CT image would be re-
quired to accurately classify the spa-
tial distribution of recurrence into 
“in-field”, “out-field” or “marginal”. 
In-field recurrence would normally 
be expected in a proportion of head 
and neck cancer patients treated 
by either IMRT or conventional 
irradiation techniques. Out-field 
misrepresents the inadequacy of 
clinical target volume delineation in 
IMRT plans or an untreated, previ-
ously undetected malignant focus. 
Clearly, it would be both impractical 
and inappropriate to conduct a large 
randomized clinical trial address-
ing progression-free and/or overall 
survival in patients with head and 
neck cancer treated by IMRT. As 
such, marginal misses, which test 
the deleterious effects of dramatic 
dose gradients, would pose as an 
important variable in assessing the 
safety of IMRT delivery. Obviously, 
not all marginal misses would be 
expected in areas of parotid sparing. 
Nonetheless, reporting such data is 
pertinent for the sake of comple-
tion.         
We applaud Nutting and col-
leagues1 for this landmark trial 
which adds significantly to the 
scarce level I evidence support-
ing the use of IMRT in head and 
neck cancer.5 However, we encour-
age all head and neck radiation on-
cologists to meticulously assess and 
report the spatial distribution of 
locoregional recurrence in order to 
fully evaluate the safety and justify 
the widespread implementation of 
IMRT for parotid-sparing in head 
and neck cancers. 
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